Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.

Japanese journal of clinical oncology - 1 Jun 2006

Lee Kyung-Hun, Han Sae-Won, Hwang Pil Gyu, Oh Do-Youn, Kim Dong-Wan, Chung Doo Hyun, Im Seock-Ah, Kim Tae-You, Heo Dae Seog, Bang Yung-Jue

Abstract excerpt

BACKGROUND: The association of epidermal growth factor receptor (EGFR) mutations with the response to conventional cytotoxic chemotherapeutic agents in non-small-cell lung cancer patients has not been investigated. We retrospectively analyzed the associations between response to chemotherapy and molecular markers associated with gefitinib responsiveness including EGFR mutations. METHODS: EGFR (exons 18, 19 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Deoxycytidine
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gemcitabine

Share to Genes, erbB-1

Share to Genes, ras

Share to Paclitaxel

Share to Proto-Oncogene Proteins c-akt

Share to Quinazolines

Source

Identifiers

PMID: 16818479
DOI: 10.1093/jjco/hyl039

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.PMID 16818479Read ↗

Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status.Semantic proximity Read ↗

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.Semantic proximity Read ↗

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With GefitinibSemantic proximity Read ↗

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancerSemantic proximity Read ↗

From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.Semantic proximity Read ↗

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.Semantic proximity Read ↗

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling.Semantic proximity Read ↗

KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.Semantic proximity Read ↗

Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.Semantic proximity Read ↗

EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients.Semantic proximity Read ↗

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.